Abicipar pegol: Phase III started

Allergan began the double-blind, sham-controlled, international Phase III SEQUOIA and CDER trials to compare 2 dosing schedules of 2 mg intravitreal abicipar pegol vs. Lucentis ranibizumab for 96 wee...